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Preterm birth is one of the most common causes of neonatal morbidity and 
mortality. The incidence of preterm birth can be reduced by treatment with vaginal 
progesterone or cervical pessary. However, no studies have supported a treatment 
regimen that can reduce preterm birth in twin pregnancies. In this study, we will 
examine whether a combination therapy of vaginal progesterone and cervical 
pessary can reduce preterm birth in women with dichorionic-diamniotic twin 
gestations. We will enroll pregnant women with dichorionic-diamniotic twins at 11-
14 weeks’ gestation from a local hospital in a randomized control trial. This novel 
approach may help establish a new management option for twin pregnancies and 





CHAPTER 1: INTRODUCTION  
1.1 Background 
1.1.1 Preterm birth epidemiology in the United States  
Preterm birth is defined as delivery prior to 37 completed weeks of gestation 
and is one of the most common complications of pregnancy.1,2 In the United States, 
preterm birth is the most common cause of neonatal morbidity and mortality 
accounting for at least one-third of infant deaths and is the second most common cause 
of death in children under 5 years of age.3,4 Preterm neonates that are born before 32 
weeks of gestation are at a higher risk of complications, such as respiratory distress 
syndrome (RDS), intra ventricular hemorrhage (IVH), and necrotizing enterocolitis 
(NEC).4,5 Premature newborns may require prolonged hospitalization and lifelong 
medical treatments.4,6 While various etiologies account for preterm delivery, one of 
the major risk factors for preterm delivery is multiple gestations (i.e. twins and higher 
order multiples). 
The rate of twin births has risen 76% from 1980 to 2009, and the rate of 
preterm delivery among multiple gestations has also increased during this time 
period.8 Studies have shown that there is a causal effect between twin pregnancies and 
preterm birth.7,8 Other studies have also discovered that the rate of preterm births due 
to twin pregnancies has increased from 11.8% in 1995 to 16.7% in 2013.7  In the 
United States, twins account for 10% of premature births and about 23% of all preterm 
births that occur before 32 weeks of gestation.9 Twins can suffer from both 
spontaneous and indicated preterm births, but more than 70% of preterm births in 
multiple gestations are spontaneous.13 Increased incidence of twin gestations 
combined with their increased preterm birth in twin gestations is one of the major 





Twins born prematurely have a 4 times higher risk of mortality when compared to a 
singleton born at the same gestational age.10 Similarly, late preterm birth (gestational 
age between 34 weeks 0 day and 36 weeks 6 days) has a minimal effect on increasing 
mortality in singletons. However, late preterm births in twins lead to 3 times higher 
risk of mortality.7 Overall, premature birth is responsible for greater than 50% of all 
neonatal deaths for multiple gestations.11 Although a great deal of effort has been 
placed into reducing the incidence of preterm births, the majority of these efforts are 
being focused on singleton pregnancies.7-11 As a result, the effectiveness of 
interventions to reduce preterm births in twin pregnancies is not well understood.7-10 
Given that this is a high-risk population, a greater emphasis needs to be placed on 
establishing effective interventions to reduce the rate of preterm births in twin 
gestations.  
 
1.1.2 Screening for Preterm Births  
Accurately predicting preterm delivery has been challenging in patients 
without a history of prior preterm delivery. Currently, transvaginal ultrasound (TVU) 
is used to measure cervical length to stratify patients for risk of cervical insufficiency 
and preterm delivery.12 Screening asymptomatic singleton pregnancies with TVU is 
usually done between 16 and 23 weeks’ gestation.12,19 In singleton gestations, a 
cervical length of less than 35mm is considered short, and if it is less than or equal to 
20mm, vaginal progesterone treatment is indicated.12,19 Asymptomatic multiple 
gestation TVU screening is not recommended in clinical practice, despite carrying a 
higher risk than singleton gestations, because there are no effective treatment 
modalities developed for multiple gestations yet.12 Even with screening, predicting 





cervical length and risk of preterm labor is not as well understood in these cases.12,19 
Since spontaneous preterm births are much more common than indicated preterm 
births in twin pregnancies, observing and waiting for the cervical length to change 
could delay proper treatment.  
 
1.1.3 Current Treatment Options for Reducing Preterm Deliveries in Multiple 
Gestations 
Currently, limited treatment options are available to patients with multiple 
gestations that are at a high risk of delivering prematurely. Studies have shown that 
progesterone supplementation significantly decreases the rate of preterm birth in high-
risk singleton pregnancies.7 During the past several decades, multiple studies have 
attempted to discover effective treatments that could lower the incidence of premature 
birth in twin pregnancies and delay birth to increase the gestational age.13-16 Treatment 
modalities, such as intramuscular 17 alpha-hydroxyprogesterone or natural vaginal 
progesterone, that were effective in preventing premature birth in singleton 
pregnancies, did not show the same benefit in twin pregnancies.15,16 Additionally, 
utilizing higher dose vaginal progesterone did not demonstrate any benefit.17 While 
progesterone may not be effective at preventing preterm birth in twins, combining it 
with a cervical pessary may produce a greater therapeutic response.13-16  
Cervical pessary is a round silicone medical device placed at the opening of 
the cervix in women at risk of preterm birth, usually between 16 weeks and 22 weeks 
of gestation, has shown conflicting results.18,19,31 Studies have shown it can reduce 
preterm birth before 34 weeks of gestation in singleton pregnancies with a short 
cervical length/cervical insufficiency.19,20 However, there are no changes in neonatal 





could not duplicate these results and found no difference.19-21 Studies that specifically 
utilized cervical pessary in unselected twin pregnancies found no overall treatment 
benefit in the pessary group, but the results showed that it significantly decreased 
premature birth rates before 32 weeks’ gestation in a certain population of women 
with cervical insufficiency who had a cervical length was less than the 25th percentile 
(< 38mm).19,24, Furthermore, the rate of composite perinatal outcomes was 
significantly lower in this subgroup of women compared to the placebo group.22-24  
Although the effects progesterone and cervical pessary have shown conflicting 
results across studies, it does reveal that they might have a potential as a treatment 
modality, especially for women with twin gestations and cervical insufficiency.19,25,26 
Because cervical shortening can be detrimental to twin pregnancies, resulting in 
preterm birth and severe neonatal morbidity and mortality, it might be beneficial to 
utilize a cervical pessary with progesterone since it has not been shown to cause any 
negative side effects.18,19,24-26 Generally, a cervical pessary is inserted around 16 to 22 
weeks’ gestation for both singleton and twin pregnancies.19 This new intervention 
might potentially improve outcomes by implementing it alongside daily vaginal 
progesterone between 11 to 14 weeks, which will be continued until the twins are 
delivered or until 38 weeks’ gestation.19  
 
1.1.4 The Role of Supplemental Progesterone on Reducing Preterm Birth Risk  
Progesterone is a steroid hormone that has essential roles throughout 
pregnancy and is involved during the delivery process.16,27 It is imperative in the 
process of uterine contractions, sustains decidualization, and has a role in promoting 
the immunity of the mother against fetal semi-allografts.27 A number of studies have 





Progesterone hormone receptors are found throughout the uterus and cervix and 
regulate the effects of progesterone in pregnancy.27 Progesterone’s effects on the 
myometrium in the uterus allows for remodeling to facilitate the growth of the 
fetus.27,28 Progesterone produced by the placenta, ovaries, and adrenal glands maintain 
uterine quiescence to prevent the onset of labor.16,27,28It inhibits the propagation of 
uterine contractions by preventing the synthesis of cell gap junctions in the 
myometrium.27 Additionally, it acts to inhibit oxytocin and prostaglandin signals that 
are involved in the initiation of the parturition process.27 The integrity of the cervix, 
which further facilitates gestation, is maintained through the actions of progesterone 
which prevents the breakdown of collagen in the cervical stroma.27  
Low serum levels of progesterone have been correlated with an increased risk 
of preterm birth and threatened miscarriage.19,27,29 Generally, when a woman has 
reached full term of gestation, a reduction in progesterone levels or modulation of 
progesterone receptors results in the onset of labor.29 This is associated with an 
increase in uterine contractility, which is subsequently followed by the delivery of the 
fetus.29 Thus, women that have a suboptimal level of progesterone production are at 
risk of early delivery.19,29 As a primary preventative measure, there has been a 
particular focus on the role of supplemental progesterone on reducing the risk of 
preterm delivery. The route of administration has been shown to have immense effects 
on the efficacy and safety of its use in the prevention of preterm delivery.19,27,29 It is 
been advised that oral progesterone should be avoided given that first-pass hepatic 
metabolism reduces its bioavailability, while simultaneously exposing the mother to 
an increased risk of side-effects.16,27 Vaginal administration of progesterone bypasses 
first-pass hepatic metabolism and has local endometrial effects, is rapidly absorbed, 





administration is considered to be safe in pregnancy and has been approved by the 
United States Food and Drug Administration (FDA) in 2011.16 A number of studies 
have shown that progesterone supplementation in pregnancy can have the same effects 
as endogenous progesterone and consequently facilitate fetal growth, maintain 
gestations, and prevent early onset labor by impeding uterine contractility, thus 
reducing the risk of preterm deliveries and consequent neonatal morbidity and 
mortality.16,17,27-29 Although progesterone supplementation in pregnancy has been 
proven to have significant positive outcomes in singleton pregnancies, the effect of 
this intervention on multiple pregnancies is still not well understood.16,17,27-29  
 
1.1.5 The Future of Interventions for Treatment of Preterm Births in Multiple 
Gestations 
Novel and effective treatments are urgently needed to decrease the incidence 
of preterm birth, and subsequent neonatal morbidity and mortality, in twin gestations. 
A prospective open-label randomized controlled clinical trial is proposed to 
investigate the utility of late first trimester combined vaginal progesterone and 
cervical pessary use to prevent preterm delivery in unselected dichorionic-diamniotic 
(DCDA) twin gestations. This intervention differs from previous studies on twin 
preterm birth treatments because it implements cervical pessary alongside 
progesterone rather than investigating their use as monotherapies. Because this study 
consists of unselected twin gestations, cervical length would not be used for inclusion 
or exclusion study criteria. Using unselected twins allows for the intervention to start 
between 11 to 14 weeks’ gestation rather than 16 to 22 weeks, in contrast to other 
studies.19 Starting the intervention between 11 to 14 weeks’ gestation could allow for a 





pregnancies. Since a short cervical length is a major risk factor for premature birth, 
starting treatment earlier might prevent or delay the initial shortening process. Using a 
new method of implementing treatment sooner in the pregnancy might prove to 
increase gestational age.  
With multiple studies being unable to find a solution to delaying preterm birth 
in twins, unexplored novel ideas must be tested to discover an effective treatment 
intervention for this ongoing issue. Intervention involving both vaginal progesterone 
and cervical pessary can easily be introduced earlier in pregnancy and used in clinical 
practice if proven to be effective, because they are non-invasive, affordable, have no 
known adverse effects, and could potentially lead to a decrease in the overall cost of 
care.19,25  
 
1.2 Problem Statement  
Even with the significant increase in risk, incidence, morbidity and mortality, 
there are no effective treatment options for preventing preterm birth in twin 
gestations.5,6 Previous clinical trials that studied the effectiveness of interventions to 
prevent preterm birth in singleton gestations have been unable to provide statistically 
significant results for twin pregnancies.5 Novel studies must be done to explore new 
ways to effectively use these interventions to treat premature birth in twin gestations, 
or definitively determine they do not work, prompting investigation into completely 
different treatments. In either case, further research is needed to improve the severe 






1.3 Goals and Objectives 
The goal of this study is to investigate the effectiveness of combined vaginal 
progesterone supplementation and cervical pessary initiated in the late first trimester 
in prolongation of gestation and prevention of preterm delivery in unselected DCDA 
twin gestations. The primary objective of this study is to compare the effect of 
combined vaginal progesterone supplementation and cervical pessary (starting 
between 11 to 14 weeks’ gestation until 37 weeks’ gestation or birth) vs. no 
intervention in women pregnant with twins on the rate of preterm birth in DCDA twin 
gestations. Studies designed to decrease preterm birth has been done before and is an 
easy to track dichotomous outcome.  
The secondary objective of this study is to investigate the effect of this 
intervention on a composite outcome of overall gestational age; level of preterm birth 
grouped by certain gestational ages (before 35, 34, 32 and 28 weeks of gestation); 
cervical length changes throughout pregnancy; birth weight; and neonatal morbidity 
and mortality in pregnancies treated with combined vaginal progesterone 
supplementation and concomitant cervical pessary initiated in the late first trimester in 
unselected DCDA twin gestations. Neonatal morbidity and mortality will be assessed 
by determining and comparing the APGAR score; admission to and time spent in the 
neonatal intensive care unit (NICU); and composite neonatal outcomes (the 
occurrence of any of the following events: RDS, IVH, sepsis, NEC, and death before 
hospital discharge) in the intervention group and the control group.  
Comparing overall gestational age adds novelty to the study and sets it up for 
success. Because preterm birth is extremely common and difficult to treat in twin 
gestations, it is essential to conduct a study that can also establish a statistically 





significant improvements in these outcomes could also establish this intervention as 
the treatment of choice for preventing morbidity and mortality in premature twin 
gestations. 
 
1.4 Research Questions 
1. In twin gestations, without a maternal history of preterm birth, can the early (11-
14 weeks’ gestation) administration of both a daily vaginal progesterone and 
cervical pessary cause a reduction in preterm delivery rates compared to 
controls that undergo standard antenatal care? 
2. In twin gestations, without a maternal history of preterm birth, can the early (11-
14 weeks’ gestation) administration of both daily vaginal progesterone and 
cervical pessary decrease composite neonatal morbidity and mortality compared 
to controls, who will receive the standard of care? 
 
1.5 Hypothesis  
It is hypothesized that the combined use of vaginal progesterone and cervical 
pessary from 11 to 14 weeks’ gestation (until 37 weeks’ gestation) will result in a 
20% decrease in the rate of preterm births in DCDA twin gestations compared to 
women that receive standard cares during the same timeframe. 
 
1.6 Definitions  
1. Vaginal progesterone: Vaginal progesterone is a form of medical intervention 
that involves vaginally administering a tablet formulation containing either a 
natural or synthetic form of the endogenous steroid hormone progesterone.30 





results in receptor phosphorylation, the dissociation of heat shock proteins, and 
transcription activation.30 The activation of the progesterone receptor results in 
an increase in estrogen metabolism and a reduction in the number of viable 
estrogen receptors.27,29,30 Progesterone results in a decrease in uterine 
contractility in pregnancy, secretory endometrial changes, and results in the 
maintenance of pregnancy.27,30   
2. Cervical pessary: A cervical pessary is a round silicone medical device that is 
placed at the opening of the cervix. This medical device is placed early in 
pregnancy in women that are at risk of preterm birth and is removed later when 
this risk has elapsed.31 
3. Gestation: The time period between conception and birth.32 
4. Preterm: The birth of an alive neonate prior to completion of 37 weeks of 
gestation. Subcategories include moderate to late preterm (32 to 37 weeks), 
very preterm (28 to 32 weeks), and extremely preterm (less than 28 weeks).33 
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CHAPTER 2: REVIEW OF LITERATURE  
2.1 Introduction 
The purpose of this literature review was to analyze the available evidence that 
is currently available in preterm birth management in twin gestations. Additionally, it 
aimed to identify which medical intervention was most effective at preventing preterm 
birth in twin pregnancies (vaginal progesterone administration vs. cervical pessary 
plus expectant management).  
 
2.1.1 Excisional Sources 
An a-priori designed protocol model was used to perform this review. An 
electronic search of PubMed, Scopus, Ovid, MEDLINE and Cochrane was conducted 
from July 2020 to July 2021 utilizing a combination of relevant keywords, medical 
subject heading terms, and word variants for “preterm birth” and “twin pregnancies”. 
The full list of keywords used in different combinations is outlined in table 1. Another 
hand search was performed in relevant articles to determine if their reference lists 
contained any additional relevant reports. The PRISMA guidelines were followed.  
 




Multiple fetuses  
Preterm birth 





Vaginal infections  
Vaginal discharge  





Intra-uterine death  








Retinopathy of prematurity  




2.1.2 Eligibility Criteria and Main Outcome Measures 
The inclusion criteria for studies included randomized control trials in which 
twin gestations were randomized to either a control group (standard treatments or a 
placebo) or an intervention group receiving treatment for the prevention of preterm 
birth (any type of cervical cerclage, progesterone, cervical pessary, or a combination 
of these). The primary outcomes included preterm birth that was < 34 weeks of 
gestation. Secondary outcomes included: Preterm birth < 24 weeks; preterm birth < 28 
weeks; preterm birth < 32 weeks; preterm birth < 37 weeks; gestational age at delivery 
(in weeks, continuous variable); intra-uterine death (either twin after 22 weeks of 
gestation); neonatal death (either twin up to 28 days of life); perinatal death (the sum 
of intra-uterine deaths and neonatal deaths); APGAR score <7 (calculated at 5 
minutes); birthweight < 2500 g; RDS; NEC; sepsis; the need for mechanical 
ventilation; admission to the NICU. The primary and secondary outcomes were 






2.1.3 Data Collection and Analysis 
Relevant studies were extracted and reviewed by an independent third party to 
ensure the reliability and quality of included research. The risk of bias in the included 
studies was assessed through the Revised Cochrane risk-of-bias tool for randomized 
control trials. Each study was assessed for risk of bias arising from five domains: 
missing data, randomization procedures, protocol deviations, measurement, and 
reporting of results. The risk of bias was considered low if at least four of the domains 
were rated as being low risk, with at least one of these domains being random 
allocation to groups and allocation concealment. The strength of the recommendations 
and quality of the included evidence was assessed through the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) method.4  
 
2.1.4 Results 
Overall, 78 articles were identified, 64 were not included because they did not 
meet eligibility, 14 did. I especially focused on these 3 studies for the literature review 
after been deemed relevant to the current study (outlined in table 2). Other articles 
were also reviewed to look at confounders that might affect this proposed study.  
 






2.2 Effect of Vaginal Progesterone Administration and Cervical Pessary Insertion on 
Singleton Pregnancies  
A review of the effect of vaginal progesterone administration and cervical 
pessary insertion on singleton pregnancies was conducted to determine the rate of 
reduction of preterm births that could be expected from using the same intervention in 
twin gestations. A cohort study conducted by Stricker et al. (2016) in 53 pregnant 
women with singleton gestations found that treatment with combined cervical pessary 
and progesterone did not result in a reduction in preterm deliveries compared to 
cervical pessary alone.23 Delivery prior to 34 weeks of gestation occurred in 32.1% of 
participants that were given the combined intervention compared to 24.5% of 
participants that received monotherapy with cervical pessary.23 However, it was found 
that there was a reduction in admission to the NICU in women that received combined 
treatment compared to monotherapy.23 In contrast, a retrospective evaluation 
conducted by Tajima et al. (2020) on 95 pregnant women with singleton gestations 
Author  Year Country  Period 
Considered 




2019 Spain 2010 to 2014 Twin pregnancies, 
minimum maternal age 
18 years, arrested 
preterm labor, cervical 
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24 and 33 weeks  
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2017 to 2019 Maternal age older than 
18 years, 2 live fetuses 
at the 11 to 13 weeks’ 
scan, dichorionic or 
monochorionic 
diamniotic twin 
pregnancies, fluency in 
the local language  
Vaginal 
progesterone 
300mg bid from 11 to 




















found that there was a 22.2% reduction in the rate of preterm deliveries in women that 
received combined vaginal progesterone and cervical pessary compared to women that 
received tocolysis (7.0% compared to 30.8% rate of deliveries before 36 weeks of 
gestation).24 Similarly, Daskalakis et al. (2018) discovered through a prospective 
cohort study that combined vaginal progesterone and cervical pessary reduced the rate 
of preterm births in singleton pregnancies by 11.9% when compared to no intervention 
(44.4% vs. 32.5%).25 Thus, it can be expected that if similar results are observed in the 
current study, combined vaginal progesterone and cervical pessary should have an 
estimated effect in reducing preterm birth rates in twin gestations by 10 to 20%.   
 
2.3 Review of Empirical Literature on the Effect of Cervical Pessary Insertion on 
Preterm Birth Rates in Twin Gestations 
To date, there has been no intervention that has been proven to be effective in 
reducing preterm birth rates in twin gestation, particularly in cases of known risk 
factors including a cervical insufficiency and threatened preterm labor. Merced et al. 
(2019) conducted an open, randomized, controlled trial to determine if cervical 
pessaries were beneficial in preventing birth before 34 weeks of gestation in women 
with twin pregnancies with the aforementioned risk factors.1 Their results revealed 
that the use of cervical pessary vs. no intervention resulted in a significant reduction in 
birth rates before 34 weeks of gestation (16.4% vs. 32.3%).1  
Similar findings were also seen in a few other studies. A retrospective cohort 
identified women with cervical insufficiency (cervical length < 20 mm) and assessed the 
association of cervical pessary inserted before 28 weeks of gestation in twin pregnancies 
compared to no intervention.7 Findings were suggestive of lower incidence of delivery at 





severe neonatal morbidity (p=0.04).7 Others studies showed that cervical pessary 
reduced preterm birth before 34 weeks’ gestation in singleton pregnancies with a short 
cervical length.5,8 However, neonatal morbidity did not differ between the two 
groups.5,8,9  
Studies that specifically utilized cervical pessary in unselected twin pregnancies 
found no overall treatment effect in the pessary group, but the results showed that it 
significantly decreased premature birth rates before 32 weeks’ gestation in a certain 
population of women whose cervical length was less than the 25th percentile (< 
38mm).5,10 Furthermore, the rate of composite perinatal outcomes was significantly 
lower in this subgroup of women compared to the placebo group.10-12  
 
2.4 Review of Empirical Literature on the Effect of Vaginal Progesterone 
Administration on Preterm Birth Rates in Twin Gestations 
Intramuscular/vaginal has been shown to be effective in reducing the rate of 
preterm birth in singleton pregnancies, with no additional benefit at higher doses.13-16 
A meta-analysis conducted in 1990 collated evidence from 7 controlled trials for the 
outcomes of progesterone agents during pregnancy.17 Only women who were at high 
risk of preterm birth were selected and the outcomes also included neonatal morbidity 
and mortality. Overall, there was no statistical effect of progesterone agents during 
pregnancy with neonatal morbidity and mortality. However, intramuscular 17 alpha-
hydroxyprogesterone caproates did decrease the overall incidence of preterm birth.17 
There has been a renewed interest in the outcomes of vaginal progesterone for recurrent 
or at-risk mothers for preterm birth. Two clinical trials demonstrated a reduction in 
preterm birth with both natural vaginal progesterone and synthetic progesterone 





gestation on neonatal morbidities including respiratory distress are also of interest. 
Another clinical trial randomized women between 18-23 weeks with either live singleton 
or twin pregnancy with a previous history of preterm birth to administer vaginal 
progesterone. There were no major differences in the incidence of respiratory distress 
syndrome (10.5% in the intervention group vs. 10.6% in the placebo group) (95% CI 
0.69-1.53, p=0.905).20 There were also no differences in the rate of maternal morbidities 
associated with side effects (9.9% in the intervention group vs. 7.3% in the placebo 
group) (95% CI 0.85-2.15, p=0.204).20 Overall, data has not been conflicting regarding 
neonatal outcomes yet there is improved gestational age when vaginal progesterone is 
administered at 18-23 weeks.19,20  
Rehal et al. (2021) aimed to determine if the positive effects of vaginal 
progesterone could be extrapolated to multiple gestations. They conducted a 
randomized, placebo-controlled, double-blind trial to determine if the administration 
of daily vaginal progesterone 600mg from 11 to 14 weeks until 34 weeks’ gestation in 
twin pregnancies influenced the rates of spontaneous preterm births. They observed a 
spontaneous births between 24 to 34 weeks of gestation among the intervention group 
of 10.4% in the progesterone group compared to 8.2% in the placebo group (95% CI 
0.88-2.05, p=0.17).2 However, they were able to find a minor benefit in preventing 
preterm birth prior to 32 weeks’ gestation in those with a cervical length of < 30mm 
(p=0.08).2 This indicates that progesterone may be beneficial in preventing preterm 
birth between 24 to 32 weeks of gestation, however, this beneficial effect might not 
extend to the third trimester of pregnancy.  
Shabaan et al. (2018) performed a randomized, open-label, controlled trial on 
70 pregnant women with twin pregnancies to determine the effect of vaginal 





rates to women receiving no additional treatment beyond standard care. Unlike 
Merced et al. (2019), Shabaan et al. (2018) did not observe a statistically significant 
difference between preterm birth rates (delivery < 37 weeks) in women receiving 
vaginal progesterone and the control group (16.9% vs. 25.4%, p=0.06).1,3 
Furthermore, Shabaan et al. (2018) found that the mean gestational age between the 
two groups was similar.3   
 
2.5 Effect of Vaginal Progesterone and/or Cervical Pessary on Preterm Birth Rates in 
Twin Gestation  
A randomized controlled trial compared the efficacy of cervical pessaries with 
vaginal progesterone for twin pregnancies at 16-22 weeks among women who had a 
cervical length < 38 mm.21 They observed a 16% (n=24) preterm birth rate < 34 weeks’ 
gestation in the cervical pessary group compared to 22% (n=33) in the progesterone 
group.21 Those with cervical insufficiency who had a cervical length of < 29 mm, 
pessary reduced the birth rate before 34 weeks from 46% (n=16) to 21% (n=10) with 
improvement in perinatal outcomes.21 Although progesterone and cervical pessary have 
shown conflicting results, these studies reveal that they also show promising ones, 
especially for women with twin gestations and cervical insufficiency.5,22  
The combined use of vaginal progesterone and cervical pessary has also been 
observed in twin pregnancies to determine the outcome of preterm births at 18-27 
weeks of gestation.26 Among women with cervical insufficiency (cervical length of < 
26 mm), there were no statistical differences between intervention and standard of 
care groups for preterm birth < 34 weeks (40.0% in the intervention group vs. 18.8% 
in the standard of care group, p=0.07).26 In terms of the birthweight, there were also 





However, an important predictor of preterm birth (< 34 weeks) in ongoing pregnancy 
for women receiving both vaginal progesterone and cervical pessary in mothers with 
twin pregnancies was the previous history of preterm birth (< 37 weeks) (p=0.031).26 
A recent meta-analysis reviewed the outcomes of vaginal progesterone, cervical 
pessary and cervical cerclage among women with twin pregnancies and short cervical 
length (< 26 mm) with no risk in reduction of preterm birth < 34 weeks.27 
 
2.6 Review of Empirical Literature on the Effect of Vaginal Progesterone and/or 
Cervical Pessary on the Rates of Neonatal Morbidity and Mortality  
In addition to reducing preterm birth, an important factor to measure is whether 
the intervention decreases neonatal morbidity and mortality. Although Merced et al. 
(2019) observed a significant reduction in the rates of spontaneous preterm births in 
pregnant women that received a cervical pessary, they did not observe a significant 
reduction in composite neonatal mortality..1 However, they did note statistically 
significant reductions in neonatal birth weight less than 2500g, neonatal sepsis, and 
NEC in the group that received cervical pessaries.1 Conversely, Rehal et al. (2021) 
noted that the administration of vaginal progesterone did have a significant reduction 
in the rate of neonatal mortality.2 They also noted that this intervention had a 
significant reduction in neonatal respiratory distress syndrome, birth weight less than 
1500g, and the need for mechanical ventilation.2 Unlike Rehal et al. (2020) and 
Merced et al. (2019), Shabaan et al. (2019) observed no difference in neonatal 
mortality and morbidity in women that received vaginal progesterone during 






2.7 Review of Studies to Identify Potential Risk Factors/Confounders 
There are many potential confounders for preterm birth such as baseline 
genotypes, biochemical variables, lifestyle characteristics, socioeconomic status, 
education level, etc., that have not been included in many previous studies and are 
beyond the scope of this study. It is important to consider the potential for these 
variables to act as confounding factors when evaluating the outcomes of the discussed 
studies and when analyzing the results of the proposed study.  However, there are 
many risk factors that should be measured and adjusted for in the proposed study.  
 
2.7.1 History of Preterm Birth  
The most important risk factor that predicts preterm birth is a prior history of 
preterm birth.45 The risk increases further if there was a history of more than one 
preterm birth.45 If the gestational age was smaller, it further increases the risk of 
preterm birth.45 For a twin gestation among mothers who have had a preterm singleton 
gestation, the chance of recurrence is 57% (95% CI: 51.9-61.9).46 As twin pregnancy 
itself is a risk factor for preterm birth, when compounded with a prior history of 
preterm birth, it has a significant impact on the rate and severity of preterm birth.45,46   
 
2.7.2 Maternal Risk Factors  
  There are notable ethnic disparities to consider with preterm birth. A meta-
analysis conducted by Schaaf et al. (2012) highlighted the risk of preterm birth as 
higher among non-white women (odds ratio=2.0, CI:1.8-2.2) when compared to 
Caucasian mothers.28 However, findings demonstrated that while the rates of preterm 
birth were higher among non-white women, the neonatal outcomes were better among 





important risk factor for preterm birth. Women who are extremely underweight with a 
BMI of < 17 kg/m2 have a higher risk of preterm birth (odds ratio=2.4, CI: 1.4-4.2).29 
Potential reasons include macro-and micronutrient deficiencies that impair detail 
growth. Also, women who are obese with a BMI >34.9 kg/m2 are also at increased 
risk of developing premature rupture of membranes (odds ratio=1.6, CI: 1.1-2.3).29 In 
these women, the circulating inflammatory agents are suspected to increase the rate of 
preterm birth.29  
Mothers who are actively smoking are also known to contribute to an 
increased risk of preterm births.30 There have been many studies that have reported 
the risk of smoking during pregnancy with very high rates of preterm births among 
women. A meta-analysis demonstrated that the rate of preterm births significantly 
reduced following a reduction in mothers who were smoking.31,32  
 
2.7.3 Excisional Cervical Procedures  
  Preterm birth is frequently observed among women with a short cervix.33 The 
use of cervical cerclage has been present since the 1950s for women with cervical 
insufficiency.34 Overall, the outcomes of prophylactic cerclage have remained 
unclear.34 A study reviewed the outcomes of cerclage among women who had 
undergone conization.35 While there was no significant contribution relating to age or 
years from conization, conization followed by cervical cerclage increased the risk of 
preterm birth.35 Potential contributors include inflammation following cervical 
cerclage and ensuing intra-amniotic inflammation resulting in elevated preterm birth 
rates.35 The risk of developing spontaneous preterm birth < 35 weeks among women 
who have had a history of the excisional procedure is 13%.35 A meta-analysis 





electrosurgical excision and preterm birth.36 Overall, there was a higher risk of 
presenting with preterm birth < 37 weeks following loop electrosurgical excision 
procedure (LEEP) (pooled relative risk= 1.60, 95% CI: 0.99-2.55), but these findings 
were not statistically significant.36 Another meta-analysis conducted by Danhof et al. 
(2015) compared the risk of preterm birth among women who had an excisional 
procedure for cervical intraepithelial neoplasia prior to and while pregnant, to women 
with cervical intraepithelial neoplasia that remained untreated.37 The outcomes 
suggested that women who were treated during pregnancy had the highest risk of 
preterm birth (OR=6.5, 95% CI: 1.1-3.7).37  
A study conducted by Goldenberg et al. identified that a cervical length < 25 
mm at 24 weeks was a strong predictor of preterm birth in twin pregnancies (odds 
ratio= 6.9, 95% CI: 2.0-24.2).38 A meta-analysis presented interesting findings 
concerning cervical length and early preterm birth for twin pregnancies. A cervical 
length < 26 mm was shown to have a positive likelihood ratio of 9.6 (95% CI: 5.8-
14.8) when screened at 20 weeks.39 While there is are no guidelines for the benefits of 
screening for cervical length or cervical insufficiency, many preventive strategies are 
being considered for twin pregnancies.39 
 
2.7.4 Uterine Anomalies  
 Various uterine abnormalities such as the uterine didelphys, unicornuate uterus 
uterine septum, and bicornate uterus contribute to preterm birth.40 A retrospective 
study identified 203 women with singleton pregnancies who had a uterine anomaly. 
The odds of having a preterm birth increased by 5.9 (95% CI: 4.3-8.1).40 Another 





with septate uteri (risk ratio=2.14, 95% CI: 1.48-3.11) and unification defects (risk 
ratio=2.97, 95% CI: 2.08-4.23).41  
 
2.7.5 Curettage History  
Women who have had a history of pregnancy loss either due to termination 
(abortion) or miscarriage and have been managed with cervical dilation and curettage 
are known to be at higher risk of developing spontaneous preterm birth (odds 
ratio=1.66, 95% CI: 1.14-2.42).42 The risk rises with a higher number of curettage 
procedures.43 A meta-analysis conducted by Saccone et al. (2016) identified that a 
spontaneous abortion (odds ratio=1.19, 95% CI: 1.03-1.37) and termination of 
pregnancy (odds ratio=1.52, 95% CI: 1.08-2.16) were both independent predictors of 
spontaneous preterm birth.44  
 
2.7.6 Bacterial Vaginosis  
Bacterial vaginosis is due to an overgrowth of certain bacteria in place of 
normal vaginal lactobacilli. A meta-analysis conducted by Leitich et al. among 30,518 
indicated that bacterial vaginosis doubled the risk for preterm birth (odds ratio=2.16, 
95% CI: 1.56-3.00).47 However, the impact of bacterial vaginosis on twin pregnancy 
remains unclear. Another meta-analysis demonstrated a weak association of bacterial 
vaginosis in twin pregnancies.38 A Cochrane review identified no impact on preterm 
birth rates among singleton pregnancies, high- and low-risk.48 However, another 
Cochrane review concluded that treatment of bacterial vaginosis reduced the preterm 
birth rate among high-risk singleton pregnancies (relative risk= 0.64, 95% CI: 0.47-





bacterial vaginosis have shown efficacy for preterm birth < 37 weeks (relative risk= 
0.60, 95% CI: 0.42-0.86).49  
 
2.7.7 Group B Streptococcus Maternal Colonization  
A meta-analysis conducted by Bianchi-Jassir et al. (2017) estimated the risk 
ratio for preterm birth associated with maternal Group B streptococcus (GBS) 
colonization to be significant.50 GBS colonization in mothers has been shown to 
increase the risk of preterm birth (odds ratio=1.98, p<0.001, 95% CI: 1.45-2.69).50 
Bacteriuria as an ascending infection is known to increase the risk of preterm birth 
associated with maternal GBS.50 A retrospective cohort identified the burden of GBS 
at 14 weeks of gestation in singleton pregnancies. The incidence of preterm birth was 
significantly higher among the GBS-positive mothers (p=0.001).51 
 
2.7.8 Fetal Anomalies 
The risk of preterm birth for pregnancies associated with congenital fetal 
anomalies varies upon the type of anomaly.52 Overall, the gastrointestinal anomaly 
was associated with a 2.62-fold increase in the odds of developing a spontaneous 
preterm birth (95% CI: 1.52-4.53).52 After adjusting for maternal age, ethnicity, 
tobacco and substance use, and BMI, the risk of preterm birth increases by 4.81 fold 
(95% CI: 2.86-8.09) with gastrointestinal anomaly and 3.66 fold (95% CI: 1.06-12.64) 
for neck mass anomaly.52  
 
2.7.9 Compliance with Vaginal Progesterone  
Compliance is assessed by the patients returning medication packs, diaries, 





expected doses. A study observed adequate compliance to be 80% or more among 
women taking vaginal progesterone.53 Overall, over 82% (n=1011) of the women had 
a compliance of over 80% in the trial.50 Two other studies reported a high compliance 
rate of 93-96% among women for gel forms of vaginal progesterone.33,54 Another 
form of vaginal progesterone including oil-in-capsule was less easy to use and 
associated with higher vaginal discharge.55 However, the overall satisfaction of 
vaginal progesterone is higher than that of intramuscular progesterone.56  
 
2.7.10 Gestational Diabetes  
 For twin pregnancies, the risk of adverse outcomes with gestational diabetes 
mellitus (GDM) is known to increase.57-59 A retrospective cohort study identified the 
outcomes of twin pregnancies among mothers with GDM. There was a higher risk of 
poor perinatal outcomes except for macrosomia.57 The risk of preterm birth was 
increased by an OR of 58.82 (95% CI: 31.25-135, p<0.0001) among GDM mothers 
expecting twins.57 Another study reported a lack of clear guidelines to manage 
patients with twin GDM pregnancies.58 Overall, twin GDM pregnancies had a higher 
risk of prematurity and perinatal mortality.58 There was also a higher rate of perinatal 
mortality among twin GDM pregnancies compared to singleton pregnancies 
(p=0.001).58 There are poorer outcomes of GDM with twins vs. singleton GDM 
pregnancies.59 These women are known to be in a high-risk group with a lack of 
clarity on dietary requirements, the timing of delivery, and glucose targets.59  
 
2.8 Review of Empirical Literature on the Relevant Methodology of Studies  
Merced et al. (2019) conducted an open, randomized, controlled trial in 132 





gestation and < 10 mm between 30 and 33 weeks of gestation) and did not deliver 48 
hours after an episode of threatened preterm labor. This trial was conducted between 
December 2010 and December 2014 in Barcelona, Spain, with ethics approval from 
the hospital ethics committee. Inclusion criteria for the study included a minimum 
maternal age of 18 years, twin pregnancies, and gestational age between 24 and 33 
weeks with a short cervical length and arrested preterm labor. Exclusion criteria 
included women with a cervical cerclage in situ, history of a cone biopsy, active 
vaginal bleeding or ruptured membranes, and women with regular uterine contractions 
despite tocolytic agent administration. The participants (n=132) were then randomized 
into a pessary group (n=67) and control group (n=65). The pessary group had the 
insertion of a cervical pessary, while the control group received routine management. 
The participants were followed up on a monthly basis, with no women lost to follow 
up. The methodology utilized by Merced et al. (2019) had a clear aim with an 
appropriate and justified approach. The methodology was presented with a high 
quality of detail to ensure that replication was possible. It was noted that Merced et al. 
(2019) placed the cervical pessary in participants after 24 weeks of gestation. Hence, it 
is not known whether earlier placement of the cervical pessary would have resulted in 
a greater effect on the reduction in the rate of preterm deliveries.  
The methodology employed by Rehal et al. (2021) was similar to that of 
Merced et al. (2019) but on a larger scale. They recruited pregnant women with twin 
gestations from 22 hospitals across Europe (n=1194). Inclusion criteria for recruitment 
included pregnant women that were 18 years or older, 2 lives fetuses at 11 to 13 
weeks’ scan, monochorionic diamniotic twin pregnancy, and fluency in the local 
language. The eligible participants were assigned 1:1 to an intervention group and a 





received a progesterone capsule to be vaginally administered while the control group 
received a placebo capsule to be vaginally administered that was the same size and 
shape as the progesterone pill. The intervention was commenced between 11 to 13 
weeks of gestation. The method differed from Merced et al. (2019) at this point, as the 
inclusion of a placebo allowed for double-blinding in the study. All the participants, 
investigators, pharmacists, etc. were blinded to the allocation of the participants until 
the end of the study. All participants were asked to administer one vaginal capsule 
300mg twice daily until 34 weeks’ gestation or in the event of an unexpected early 
delivery. All participants were followed up once every two weeks. The methodology 
outlined by Rehal et al. (2021) was very detailed to allow for future reproduction. No 
concerns were noted on the analysis of the method outlined by Rehal et al. (2021).  
Shabaan et al. (2018) conducted an open-label, randomized, controlled trial 
across three tertiary care centers in Egypt between 2015 and 2017. The inclusion 
criteria included pregnant women at 28 weeks of gestation that were naturally 
conceived, no known major fetal abnormalities, dichorionic diamniotic twins, and 
uncomplicated pregnancy. In total, 158 women were recruited to participate in the 
study, of which 18 were excluded due to not meeting the eligibility criteria. The 
participants (n=140) were randomly assigned 1:1 into two groups, an intervention 
group, and a control group. They determined that both groups had comparable 
baseline characteristics. The intervention group received 400mg once daily at bedtime 
from 28 weeks’ gestation. The control group received standard care. The pregnant 
women were followed up once every two weeks until delivery. The primary outcome 
of the study was the rate of premature birth prior to 37 weeks’ gestation. Rehal et al. 
(2021) had conducted a study to observe the effects of vaginal progesterone on 





gestation to 34 weeks’ gestation. They had determined that progesterone 
administration had resulted in a reduction in preterm rates before 24 weeks’ gestation, 
but did not have a statistically significant effect after 24 weeks. Thus, the lack of 
effect that was noted by Shabaan et al. (2018) may be due to the late administration of 
progesterone, as their methods commenced the trial from 28 weeks onwards. An 
earlier administration of progesterone, as was conducted in the methods by Rehal et al. 
(2021), may have resulted in more significant results. Additionally, the sample size in 
the study conducted by Rehal et al. (2021) was much larger than that of Shabaan et al. 
(2018) (n=1194 vs. n=140). This larger sample size would have allowed for 
statistically significant results to be discovered, whereas associations may have been 
missed in the analysis conducted by Shabaan et al. (2018).  Furthermore, a larger 
progesterone dose was used in the methods employed by Rehal et al. (2020) compared 
to Shabaan et al. (2018) (300 mg twice daily compared to 400 mg once daily). This 
larger dose of progesterone may have had a greater therapeutic effect and thus had a 
greater effect on preterm labor rates and postnatal outcomes. This would explain the 
positive effect that Rehal et al. (2021) observed in neonatal mortality and morbidity 
rates in women that received progesterone, compared to no effect in the study 
conducted by Shabaan et al. (2018). Rehal et al. (2021) also noted that progesterone 
administration reduced preterm birth rates in women before 24 weeks’ gestation 
compared to no effect in the study conducted by Shabaan et al. (2018). A strength of 
the study conducted by Shabaan et al. (2018) was their analysis of the characteristics 






2.9 Review of Empirical Literature to Identify Limitations and Possible Risk of Bias 
The study conducted by Merced et al. (2019) contained a sample size of 132 
participants which is small and could raise questions about the validity of the results. 
Also, the sample size allowed for a power of 80% which is on the lower end of the 
acceptable spectrum and gives rise to the potential for a type II error. Hence, there is a 
possibility that the study conducted by Merced et al. (2019) may have had false 
clinical implications. Furthermore, Merced et al. (2019) did not calculate a p-value for 
their results to demonstrate the statistical significance of their data. As opposed to 
Merced et al. (2019), Rehal et al. (2021) included a placebo in their control group that 
allowed for double-blinding in their study. Thus, they had a reduction in their level of 
potential bias compared to Merced et al. (2019). Rehal et al. (2021) did calculate a p-
value for their results, but was not statistically significant for their primary outcome 
(p=0.17). Furthermore, the large sample size utilized by Rehal et al. (2021) further 
ensured that the study had a low risk of bias and was generalizable to the population. 
Another limitation of Rehal et al. (2021) was that unlike Merced et al. (2019), they did 
not consider confounding factors such as cervical length in their analysis of their data. 
This may negatively influence the external validity of their results.  
Unlike Merced et al. (2019) and Rehal et al. (2020), Shabaan et al. (2018) 
included only women that were naturally conceived as part of their inclusion criteria. 
Women that undergo artificial reproduction are at an increased risk of miscarriage and 
preterm birth. Thus, there is a potential for bias in the studies conducted by Merced et 
al. (2019) and Rehal et al. (2020) if there was a greater number of women that 
conceived through artificial reproduction in one group compared to the other. 





uneven allocations can occur that may skew results. Thus, it is essential to conduct an 
analysis of the characteristics of each group to ensure that demographical factors do 
not have an impact on the validity of the results. This analysis was not conducted by 
Merced et al. (2019) and Rehal et al. (2020).  
 
2.10 Conclusion 
Thus, previous studies have investigated the effects of monotherapy with 
cervical pessaries and vaginal progesterone administration on the effects of preterm 
birth rates and neonatal mortality and morbidity in twin gestations. The three studies 
chose to be reviewed in depth have demonstrated that the administration of cervical 
pessary resulted in a reduction in preterm birth rates. However, there was a mixed 
result noted in investigations on the effect of using vaginal progesterone on the rates 
of preterm births. Rehal et al. (2020) noted that the use of vaginal progesterone 
reduced the rates of preterm birth prior to 24 weeks’ gestation, but did not influence 
preterm birth rates between 24 to 38 weeks’ gestation in twin gestation. Conversely, 
Shabaan et al. (2018) found no association between the use of vaginal progesterone 
and preterm birth rates in twin gestation. The difference in these results may be due to 
disparities between the methodology employed by these two studies. It was further 
noted that the use of cervical pessaries did not have an effect on neonatal mortality but 
did reduce the incidence of morbidity. Rehal et al. (2020) observed a reduction in both 
neonatal mortality and morbidity with the use of vaginal progesterone during 
pregnancy. In contrast, this reduction was not observed by Shabaan et al. (2018) who 
found no association between neonatal mortality and morbidity with the use of vaginal 
progesterone. Again, this difference may be related to the differing methodology 





To date, there has been no study that has investigated the effect of combined 
cervical pessaries and vaginal progesterone administration on preterm delivery rates in 
twin gestation. Although cervical pessaries have been found to reduce preterm 
delivery rates in this demographic and can be used as a potential prophylactic 
intervention, their effect may be amplified with the use of vaginal progesterone. 
Furthermore, Merced et al. (2019) investigated the effect of cervical pessary insertion 
on preterm rates in twin pregnancies, but had this device inserted after 24 weeks of 
gestation. Thus, it is unknown what effect an earlier administration of this device 
would have on preterm delivery rates. Hence, this proposed study aims to fill this gap 
in the available literature by determining the effects of the early insertion of combined 
cervical pessary and vaginal progesterone on preterm delivery rates and neonatal 
mortality and morbidity in twin gestation. The insertion of combined progesterone and 
cervical pessary has been found to reduce the rates of preterm pregnancies in singleton 
gestations by 10 to 20%. It is estimated that the use of these interventions in twin 
gestations will have a similar rate of effect.  
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CHAPTER 3: STUDY METHODS  
3.1 Study Design 
This is a prospective multicenter, open-label randomized control clinical trial 
to compare combined vaginal progesterone and cervical pessary placement in the late 
first trimester (11 to 14 weeks’ gestation) in DCDA twin gestations until 37 weeks 
and 6 days’ gestation or birth vs. standard care on the rate of preterm births. The 
pregnant participants will be randomly assigned (1:1) to a Control Group (no 
intervention, standard management) versus a Treatment Group (vaginal 
progesterone and the Arabin cervical pessary placed in late first trimester in twin 
gestations). The randomization will be done using a computer-generated system with 
balanced blocks consisting of 20 patients in each block. We will also administer a 
questionnaire and do an analysis of the participants’ electronic medical records 
(EMR) to track their medical histories. 
 
3.2 Study Setting and Population 
Patients will be recruited from the twelve sites of Maternal-Fetal Medicine 
Unit Centers and sub-sites within the Maternal Fetal Medicine Units (MFMU) 
Network. The primary research will be performed at the Yale Maternal Fetal Medicine 
Center at the Yale New Haven Hospital (YNHH). It is imperative to have a large study 
consortium to ensure an adequate sample size for statistically significant results. It is 
estimated that approximately 160,000 deliveries are completed annually within the 
MFNU Network.1 Thus, MFMU clinical centers will provide a participant pool to 
conduct a large clinical trial that focuses on preterm birth in multiple gestations with 
an emphasis on establishing potential interventions.1 Furthermore, it is expected that 





generalizable given that these patients are not unique in their demographic 
characteristics.1   
The participant population in this study is pregnant individuals with DCDA 
twin gestations that are being treated by the obstetric team in the MFMU Network 
Centers and sub-sites. An invitation will be sent to the MFMU centers prior to the 
commencement of the study.  
Inclusion criteria will include DCDA twin gestation; gestational age between 
11 to 14 weeks of gestation at the time of enrolment; participant age 18 years or older; 
no know chromosomal abnormality; normal cell-free fetal DNA testing; no known or 
suspected fetal structural abnormalities; uncomplicated pregnancy. 
Exclusion criteria will include monochorionic diamniotic twin gestation; 
triplets or higher-order pregnancies; history of prior preterm delivery; smoking ≥ 10 
cigarettes per day; alcohol or illicit drug consumption; singleton gestation; cervical 
insufficiency; known uterine malformations; history of hepatic dysfunction or 
gestational cholestasis; history of thromboembolic disease; recent (within one year) or 
current malignancy; vaginal bleeding; difficulty for follow-up; cervical cerclage 
inserted prior to the study; contraindication to treatment with progesterone; women 
with progesterone and peanut allergies (given that progesterone supplements may 
contain traces of peanut)  
 
3.3 Subject Protection and Confidentiality  
To ensure the safety of participants and compliance with ethical requirements, 
ethics approval will be obtained from the Intuitional Review Board prior to the 
commencement of the study. Given that the study involves vulnerable populations 





by the Institutional Review Board. To ensure that all necessary steps are completed 
prior to the submission for ethical clearance, the online Research Ethics and Safety 
Checklist for Undergraduate Experiments (RESCUE) form will be completed. It was 
determined that the CITI Human Subjects Research training module, Clearance for 
Human Subjects Ethical Research (CHSER), Participant Information Sheet (PIS), 
Informed Consent Form (ICF), and Fieldwork Safety Plan (FSP) must be completed. 
Following this, an ethics approval document and risk assessment form should be 
conducted. All forms will be sent to the research supervisor for review and clearance 
prior to sending to the College Ethics Review Committee (CERC) at Yale. After any 
necessary changes to the documents as per the CERC are completed, the documents 
can then be submitted to the Institutional Review Board for a final ethics clearance.  
To ensure the confidentiality of all participants, the HIPAA guidelines will be 
strictly adhered to by all researchers involved in the study. The patient health 
information will be limited only to staff that has a direct need to access the 
information as part of their role in the study. Furthermore, all staff involved in the 
study will undergo proper medical ethics and HIPAA training. Jotforms will be used 
as an online HIPAA-compliant tool to allow patients to input their health information 
through a secure online form. The electronic transfer of patient information will be 
avoided unless deemed necessary. If electronic transfer is required, then patient 
information will undergo end-to-end encryption prior to transfer to ensure it remains 
secure. After the collection of all data, patient information will be de-identified prior 
to analysis to ensure that information remains confidential. Furthermore, trial 
coordinators will ensure quality control screening, verification of protocol adherence, 







We will use a consecutive sampling method for the recruitment process over a 
6-month period. All individuals with DCDA twin pregnancies attending the MFMU 
Centers before 14 weeks’ gestation will be considered for inclusion in this trial, 
provided that they do not meet any of the aforementioned exclusion criteria. The site 
coordinators at the MFMU locations will be asked to provide potential participants 
with written information about the study and the trial. Those who agree to participate 
will provide the recruitment team with the authority to release their contact 
information to the research team. Prior to inclusion in the study, eligible participants 
will be screened by midwives or gynecologists to ensure they are healthy and able to 
participate in the study. All pregnancies will be dated by crown-rump length during 
the first trimester, and chorionicity will be determined. Eligible participants who agree 
to participate in the study will then be provided with a fully detailed participant 
information sheet and with the investigators contact information for any queries or 
questions before agreeing to participation. They will then be provided with a written 
informed consent form to sign. An incentive of a $100 gift card will be given to each 
participant that completes the trial. After signing the informed consent, participants 
will have the option to drop out of the study for any reason and at any time. 
Furthermore, providers as part of the investigative team will have the option to 
withdraw the participants from the study if urgent medical reasons arise. Based on the 






3.5 Key Study Variables, Measures, and Operationalization  
3.5.1 Study Intervention  
At the time of recruitment, we will obtain a detailed medical history for all 
participants, including their medical, personal, obstetric, and menstrual history 
through both EMR and questionnaires. The gestational age will be estimated if there is 
a reliable date available. If this is not available, then the providers will obtain the  
gestational age using a first-trimester ultrasound crown-rump length. All participants 
will receive their usual antenatal care for multiple gestations, including iron and 
calcium supplements. The eligible participants (pregnant individuals) will be 
randomly allocated in a 1:1 to two groups: Group 1 (Cervical Pessary and 
Progesterone Group) will have the insertion of an Arabin cervical pessary between 11- 
and 14-weeks’ gestation, followed by administration of 400 mg of vaginal natural 
progesterone once daily. These interventions will continue until 37 weeks’ gestation. 
Group II (control group) will receive no additional treatment beyond standard care. 
The independent variable in this study will be the combination therapy of the cervical 
pessary and vaginal progesterone. The dependent variable will be the mean gestational 
age at delivery and neonatal morbidity and mortality. Control variables include 
standard antenatal care for multiple gestations. The primary outcome of interest is the 
difference in the rate of preterm birth between the intervention group and the control 
group.  The secondary outcomes include overall gestational age at delivery; preterm 
birth before 35, 34, 32 and 28 weeks of gestation; cervical length changes throughout 
pregnancy (measured in millimeters via transvaginal ultrasound); birth weight; 
APGAR score at birth and five minutes after; admission to the NICU and the time 





of morbidity and mortality (the occurrence of any of the following events: RDS, IVH, 
sepsis, NEC and death before hospital discharge).  
 
3.5.2 Follow-up  
Participants in both the treatment and control groups will be followed up 
during their antenatal visits at the multicenters every week until they deliver. During 
each visit, they will be asked to report symptoms of preterm labor such as abdominal 
colic, heaviness, cramps, and sudden expulsion of a gush of fluid. They will also be 
asked about compliance and any notable side effects from use of the daily vaginal 
progesterone. During these weekly visits, the participants will also undergo an 
ultrasonography scan to evaluate the wellbeing of the fetuses. Any complications, 
such as intrauterine growth restriction, placental abruption, preeclampsia, etc. will be 
noted during these visits. At the time of delivery, neonatal birth weight, delivery data, 
referral to neonatal care unit, and any intrapartum or postpartum events will be 
recorded. The women and neonates will continue to be followed up on a monthly basis 
for 12 months after delivery to monitor for neonatal morbidity and mortality rates.  
 
3.6 Methodology Considerations  
There are a number of confounding variables in this study, such as cervix 
shape; prior cervical operations, such as cone biopsy, LEEP, etc.; compliance to 
vaginal progesterone; fetal abnormalities; miscarriage; bacterial vaginosis during 
pregnancy; GBS carrier mother; premature rupture of amniotic membranes; GDM; 
preeclampsia; and thromboembolic event. Certain characteristics pertaining to 
maternal factors such as age, ethnicity/race, educational level, socioeconomic status, 





variables will need to be taken into consideration when completing the data analysis. 
Furthermore, the participants’ mental health status may predispose her to cervical 
disease that will be accounted for when analyzing the data. For this reason, multiple 
logistic regression analyses will be conducted in the data analyses period to control for 
any or all the listed confounding variables. 
 
3.7 Blinding of Interventions/Outcomes  
Due to the nature of this study, the participants and the medical providers 
inserting the cervical pessary will not be able to be blinded to their group allocations. 
Given that this an open-label clinical trial YNHH Investigational Pharmacy will be 
informed to distribute regular packets of progesterone to the intervention and standard 
of care group as applicable. All participants, pharmacists, investigators, and other 
research personnel will be informed of the nature of the study design, and they will 
not be blinded to the intervention during treatment, data collection, and data analysis. 
The data analysis will be performed once the data has been charted, cleaned and 
readied.  
 
3.8 Assignment of Intervention  
The randomization will be performed through a computer-generated random 
assignment system with balanced blocks to ensure equal allocation to each group. 
After the allocation to groups, the control group will be asked to attend weekly follow-
up appointments at the Yale Maternal Fetal Medical Center to receive their standard 
care and monitoring of maternal and fetal health. The intervention group will be 
booked into an urgent appointment to have the insertion of a cervical pessary prior to 





progesterone capsules to administer every night for the next week until their next 
follow-up. The subjects will receive instructions and education on how to self-
administer the vaginal capsule. The subjects will receive a week supply of daily 
vaginal progesterone capsules at each weekly follow-up appointment.  
 
3.9 Adherence  
Because one intervention modality (i.e., progesterone) is self-administered 
based on the subject’s intake location, the adherence protocol will be assessed by 
having the participant complete a log of medication taken and any missed doses and to 
return the empty packet of the previous supply. We will consider the compliance to be 
adequate for inclusion in the data analysis if the participant completed 80% or more of 
the prescribed doses, which is in line with the standard cut-off for compliance in any 
clinical trials. Furthermore, the cervical pessary will be monitored by the primary 
clinician to note any deviations subjective to the patient. We will provide 
appointments at various time to fit the participants’ schedule and transportation for 
those who need it. If a participant is unable to make an appointment, their next week’s 
vaginal progesterone packet can be ordered to their local pharmacy to pick up. 
 
3.10 Monitoring for Adverse Events  
While adverse events may occur in this clinical study, they are expected to be 
extremely rare. The primary investigator of the study will be obliged to notify the 
subjects and the medical research ethics committee if any unforeseen negative 
outcomes, adverse effects, or disadvantages secondary to participation in the study are 
observed that are greater than initially noted in the research proposal. In this case, the 





committee. An adverse event is defined as an undesirable experience that occurred to a 
participant in the study, regardless of whether this is related to the interventions. 
Adverse events that may occur due to progesterone administration include fluid 
retention/bloating, breast pain, drowsiness, depression, hot flushes, dizziness, vaginal 
discharge, abdominal pain or cramping, and more.2 Due to the vaginal administration 
method of progesterone, there are limited levels of progesterone that reach systemic 
circulation in this study, compared to other routes of administration. The main adverse 
event associated with cervical pessaries is an increase in vaginal discharge.3 All 
participants will be informed of the potential adverse effects prior to acquiring written 
consent. Furthermore, all participants will be asked to report experience any adverse 
events at each weekly follow-up visit. These adverse events will be monitored until 
the situation becomes stable or the adverse event has abated. Additional tests, medical 
procedures, or referrals to medical specialists/general physicians will be performed as 
indicated.  
A serious adverse event is defined as a medical occurrence or event that results 
in a life-threatening condition, death, permanent or significant disability, 
hospitalization, a birth defect or congenital abnormality, or is a new event in the trial 
that is likely to affect the safety of participants. In the case of a serious adverse event, 
the study will be suspended until a further review is conducted and the ethics 
committee that granted approval will be informed.  
 
3.11 Data Collection  
Data will be collected at randomization and at each weekly follow-up 
appointment at the Yale Maternal Fetal Medicine Center and other MFMU Network 





involved. All centers will list basic demographic and clinical characteristics data 
obtained from the EMR and questionnaires. This provide information on the maternal 
racial group/ethnicity, age, educational level, socioeconomic status, mental health, 
BMI, or any substance use history. These questionnaires are expected to limit potential 
confounders, and the research team will have a better estimate in the management of 
confounders as the study progresses. This will be recorded using the Epi Info software 
(Centers for Disease Control and Prevention) and documented in the subject’s study 
profile. The questionnaire will include questions about any adverse events experienced 
by the participant, results of ultrasonography, any symptoms of preterm labor, etc. If 
the participant is unable to attend the clinic for any follow-up appointment, data will 
be collected through a telephone interview where they will be asked to answer the 
questionnaire. We will also document cervical length changes throughout pregnancy 
(measured in millimeters via transvaginal ultrasound) and determine if the mother has 
cervical insufficiency. 
After the participant arrives for delivery we will review their medical record to 
acquire data on the labor, delivery, and any complications that may have arisen for the 
participant or neonates. The gestational age at delivery and whether or not it is preterm 
(< 37 weeks) will be recorded (primary outcome data), with the division of groups in 
preterm birth before 35, 34, 32, and 28 weeks of gestation (secondary outcome data). 
We will assess the birth weight of the baby as part of the standard operating protocols, 
hence no, hence no additional personnel will be required. The nursing team will ensure 
that the APGAR score at birth and five minutes after is charted correctly. Admission 
to the NICU and the time spent there if needed (of one or both twins) will be noted 
with yes and no options (dichotomous data). A set of lists for composite neonatal 





5. Death before hospital discharge will all be enlisted as dichotomous variables by the 
research assistants which will be regularly cross-checked and finally verified by the 
research heads at the different centers 
The participants will then attend a monthly follow-up appointment for 12 
months after delivery. At the first follow-up appointment after delivery, they will be 
asked about their delivery and labor details and whether any complications were 
experienced to ensure that information is not missed. Additionally, they will be asked 
screening questions for the neonates’ health status, including regular development 
questions, any symptoms of infections that may have been noted, and any concerns the 
mother has. The neonates’ weight, length, and head circumference will also be 
measured at each follow-up to monitor growth.  
 
3.12 Sample Size  
Sample size will be calculated based on a 20% reduction of the reported 60% 
preterm birth rate in twin pregnancies before 37 weeks’ gestation.4 The calculation 
was done based on Cox Proportional Hazard Regression with an α error of 0.05 and a 
β error of 20% (i.e. with a power of 80%). Accordingly, the sample size was 
calculated to be 97 participants in each arm, but when accounting for a maximum loss 
to follow-up of 25% that equates to 122 participants in each arm. The effect size 
chosen was 0.1 in order to get a larger sample size because the relationship between 
the primary outcome of gestational age and the independent variable of cervical 
pessary and progesterone is more likely to be detected with a larger sample size. 






3.13 Analysis  
Statistical analysis will be carried out on an intention-to-treat basis, thus all 
participant will be included in the results. No interim analyses will be performed. In 
cases of a strong positive effect of the combination intervention, the trial will proceed. 
Negative effects will be detected by a data safety monitoring committee. Outcomes 
will be evaluated using Cox Proportional Hazard Regression model, as well as with 
secondary outcomes looking at gestational age at birth < 35, < 34, < 32, and < 28 
weeks’ gestation. Student t-test will be used for continuous outcomes of secondary 
variables (birthweight, cervical length changes, etc.), and Chi-Square analysis will be 
used for categorical data of secondary outcomes. 
 
3.14 Timeline and Resources  
The study timeline includes 6 months for recruitment and baseline data 
collection, 12 months to assess outcomes, and 6 months for data analysis. It is 
estimated that the research team at the Yale Maternal Fetal Medicine Center at YNHH 
will include one principle investigator, one project coordinator, one project manager, 
medical providers as needed that will provide antenatal care to the participants, 
administer interventions, and collect and upload weekly follow-up data, one data 
analyst, 3-4 research assistants, five data compilers, and five data analysts. Medical 
offices as needed per site and one procedure room will be required at the Yale 
Maternal Fetal Medicine Center to conduct follow-up appointments and insert cervical 
pessaries. Cervical pessaries and vaginal progesterone capsules will need to be 
ordered. Given that all 12 MFMU Networks sites may partake in the study, there will 





The intake surveys coordinators, and data collection and entering will be led by the 
resident physicians or medical fellows. Providers will be compensated for their time. 
Additionally, equipment for the insertion of cervical pessaries, such as 
speculum, will be required. Subscriptions for the online data tools that will be used in 
this investigation will need to be organized. This includes Jotforms and the SPSS 
software package. Overall, it is expected that this study will span across a two-year 
period. It is expected to start in January 2022 and be completed by January 2024.   
 
3.15 Accounting for Loss to Follow-Up  
The primary strategy that will be utilized to avoid bias due to loss to follow-up 
and consequent missing data will be initial prevention. This will be achieved by 
careful design of the study, high level of training of staff, developing mechanisms to 
ensure that participants can be easily contacted, and implementing data quality 
procedures. Each arm of the study will include 122 participants, rather than the 
calculated 97 participants, to account for a maximum loss to follow-up of 25%. The 
secondary strategy to avoid loss to follow-up bias is to use an intention-to-treat 
methodology in analysis. Thus, even if participants drop out or are lost to follow-up, 
they will be included in the analysis of the data. Additionally, the rate of loss to 
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CHAPTER 4: CONCLUSION 
4.1 Advantages and Disadvantages  
 There are several advantages and disadvantages of the proposed study and its 
methodology that may impact the reliability of the data to be obtained. The most 
central strength of this study is the notion that we will contribute to existing literature 
since no study has been done that looks at early use of vaginal progesterone, in 
combination with cervical pessary. Other strengths of the study include the 
randomized, controlled design, which is expected to minimize bias, including bias 
from confounding factors. Furthermore, the randomized nature of the study is 
expected to enhance the generalizability of the study and combat any confounding 
variables. Additionally, there will only be a limited number of staff that will be 
involved in the insertion of the cervical pessary, which should have a positive impact 
on the validity of the study.  
The large sample size is expected to have a positive impact on the power and 
statistical significance of the results. However, this is also seen as a limitation since it 
is unknown whether obtaining such a large number of participants in a 6-month time 
period given the narrow inclusion criteria is feasible. The ultimate sample size may be 
significantly smaller than desired if a substantial number of viable participants are not 
found. Thus, the study may have to span for a longer period of time than intended to 
ensure adequate power and statistical significance. This will be addressed by 
informing the participant that they will receive optimal care and surveillance 
throughout their pregnancy, which will benefit themselves and the twins. We will also 
incentivize the participants with the $100 gift card upon completing the trial.  
A limitation of the study is that the open nature of the study with no blinding 





avoided due to the nature of the interventions. However, given that the primary 
endpoint of the study is an objective variable (gestational age at delivery), it is 
believed that the non-masked nature of the trial should not result in a significant level 
of bias. A factor that may compromise the external validity of the study is that the 
majority of women with twin pregnancies will have conceived from assisted 
reproductive technology. This consequently may have a negative impact on the 
generalizability of the results.  
A potential limitation is the lack of previous studies that have investigated the 
effects of early implementation of progesterone and cervical pessaries on the rates of 
preterm births in multiple gestations. As a result, the data cannot be compared to 
empirical evidence. However, futures studies would be able to reproduce this study 
and see if they yield different results. Also, a percentage change reduction in preterm 
births that will be expected to arise from the interventions proposed in this study was 
not based on previous studies and findings. Similar studies that were conducted in 
singleton pregnancies have demonstrated an approximately 20% reduction in the rate 
of preterm births. Thus, it is expected that the results of this study will mimic these 
results and consequently lead to a 20% reduction in the rate of preterm births in twin 
gestations with the use of progesterone supplementation and cervical pessary insertion.   
 
4.2 Clinical and/or Public Health Significance  
The use of either vaginal progesterone or cervical pessary is known to 
successfully delay preterm birth in singleton pregnancies, but no studies have provided 
statistically significant data about an intervention that prevents or delays premature 
birth in twin pregnancies.1,2 Therefore, there is no established standard of care or 





preterm birth in twin pregnancies.3 With the trend of increasing incidence of twin 
pregnancies, there are higher rates of preterm birth and higher rates of morbidity and 
mortality associated with preterm birth in this population compared to singleton 
pregnancies.4 Premature birth is responsible for greater than 50% of all neonatal 
deaths for multiple gestations; an effective treatment is needed now more than ever.5 If 
this intervention proves to be effective it can lead to a new standard of care and 
significantly decrease the morbidity and mortality that affect the majority of twin 
pregnancies.  
Because most studies look for a 50% decrease in preterm birth between the 
intervention and control group, a goal of a 20% decrease will give this study a better 
chance at success.6-10 The study is unique since it will include a multitude of important 
factors that can help determine if the intervention truly is more effective than those used 
in previous studies, even if the rate of preterm birth is not significantly reduced. Some of 
these important secondary outcomes are overall gestational age; level of preterm birth 
based on if the twins are < 35, < 34, < 32, and < 28 weeks’ gestation at birth; birth 
weight; cervical length during pregnancy; APGAR score; admission to the NICU and the 
time spent there if needed; and composite neonatal outcomes (the occurrence of any of 
the following events: RDS, IVH, sepsis, NEC and death before hospital discharge).10,11 
Discovering statistically significant improvements in these outcomes could also establish 
this intervention as the treatment of choice for preventing morbidity and mortality in twin 
gestations that are premature. 
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Appendix A: IRB Consent Form  
Instructions and invitation to participate:  
You are invited to participate in our study that aims to investigate the effect of early 
administration of vaginal progesterone and cervical pessaries on the rates of preterm 
births in twin gestations. Currently, twin gestations account for approximately 60% of 
all preterm births. This places these babies at a great risk of potential harm to their 
health. We aim to reduce this risk by devising an intervention that will reduce the 
rates of twin babies that are born preterm. In this study, you will be randomly 
allocated to a group that either receives combined vaginal progesterone and cervical 
pessary, or to a group that receives no additional interventions. We will then analyze 
your pregnancy outcomes and the outcomes of your babies and compare the rates of 
preterm births and the babies’ health status. In order to decide whether you want to 
participate in this study, we will provide you with an additional form with all of the 
risks and benefits of participation. Additionally, we invite you to have a consultation 
with our primary investigating team so that you are openly able to ask any questions 
or raise concerns. By providing you with this detailed information, we want to make 
sure that you make an informed decision regarding your participation.  
 
Economic Considerations  
There will be no monetary benefits to participating in this study.  
Audio/Video Recording 
All consultations will be recorded to assist with analysis of our data. These will be 
kept confidential and will only be used by the analysts in the study. No distribution of 
these videos will occur and they will be destroyed on the completion of the study. 
 
Please sign below if you are willing to have this interview recorded (specify audio or 
video). You may still participate in this study if you are not willing to have the 
interview recorded. 
 
 I do not want to have this interview recorded 
 I am willing to have this interview recorded 
 
Signed: _____________________________________   
     
Date: __________________        
 
Disclaimer:  
• A video recording in which the your name, likeness, image, and/or voice will 
be included will be recorded  
• By signing this form, you give us the right to make, use and publish 
Recordings in whole or in part in media forms now known (such as film, 
slides, and digital audio) or developed in the future. This includes the right to 
edit or duplicate any images/recordings 
• There will be NO reproduction, distribution, performance, or display of 
images/recordings  
• By signing this form, you relinquish the rights to inspect or approve the 
finished product or printed/published matter that uses the images/recordings 






If you are injured by this research 
In the event that any research-related activities result in an injury, treatment will be 
made available including first aid, emergency treatment, and follow-up care as 
needed. Cost for such care will be billed in the ordinary manner to you or your 
insurance company. No reimbursement, compensation, or free medical care is offered. 
If you think that you have suffered a research-related injury, contact [PI name] right 
away at [insert phone number]. 
 
Privacy/Confidentiality  
The information regarding your involvement with the study will be recorded in your 
Electronic Medical Record. From there, this information will be accessible by your 
providers who participate in managing your health. Your medical records will be 
accessible by the investigators of this study. Additionally, it is possible that the Food 
and Drug Administration (FDA) may need to review all records of participants in the 
study, however these personnel are bound by the rules of confidentiality to not 
disclose your name or information to others. Additionally, the Yale Human Research 
Protection Program Committee may access study records to conduct an internal audit. 
In this case, all members of the committee are required to keep all information and 
records confidential. All your identifiable information will remain confidential for the 
entire duration of the study. Furthermore, your data will be de-identified prior to 
analysis to ensure confidentiality. Regardless, all study personnel are legally bound by 
the rules of confidentiality and breaches of these rules will have severe legal 
repercussions.  
 
Data Sharing  
De-identified data from this study may be shared with the research community at 
large to advance science and health. We will remove or code any personal information 
that could identify you before files are shared with other researchers to ensure that, by 
current scientific standards and known methods, no one will be able to identify you 
from the information we share. Despite these measures, we cannot guarantee 
anonymity of your personal data. 
 
Clinical Trial 
This study is classified as a clinical trial and will be registered online at 
http://www.ClinicalTrials.gov. The website will not include any information that can 
identify you, but will include a summary of results once the research is completed. 
You can search this publicly-available website at any time. 
 
Taking part is voluntary  
Your involvement is voluntary, and you may refuse to participate before the study 
begins, discontinue at any time, or skip any questions/procedures that may make you 
feel uncomfortable, with no penalty. It will not harm your relationship with the 
investigators in this study or with your doctors/medical professionals. If you 
withdraw, there will be no ongoing collection of data. However, data that was 
previously collected may still be used in the analysis of the results to ensure that the 
integrity of the study is maintained. 
 
Withdrawal by investigator, physician, or sponsor 
The investigators, physicians or sponsors may stop the study or take you out of the 





experience a study-related injury, if you need additional or different 
medication/treatment, or if you do not comply with the study plan. They may remove 
you from the study for various other administrative and medical reasons. They can do 
this without your consent. 
 
If you have questions 
The main researcher conducting this study is [principal investigator’s name], a 
[professor, graduate/undergraduate student, etc.] at Yale University. Please ask any 
questions you have now. If you have questions later, you may contact [principal 
investigator’s name] at [email address] or at [phone number].  If you have any 
questions or concerns regarding your rights as a subject in this study, you may contact 
the Institutional Review Board (IRB) for Human Participants at 607-255-5138 or 
access their website at http://www.irb.cornell.edu. You may also report your concerns 
or complaints anonymously through Ethicspoint online at www.hotline.cornell.edu or 
by calling toll free at 1-866-293-3077. Ethicspoint is an independent organization that 
serves as a liaison between the University and the person bringing the complaint so 
that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
 
Statement of Consent 
I have read the above information, and have received answers to any questions I 
asked. I consent to take part in the study.  
 
Your Signature          
Date    
 
Your Name (printed)          
 
Signature of person obtaining consent       
Date    
 
Printed name of person obtaining consent       
 
This consent form will be kept by the researcher for at least five years beyond the end 






1.  IRB Consent Form Templates | Cornell Research Services. 
Researchservices.cornell.edu. https://researchservices.cornell.edu/forms/irb-consent-







Appendix B: Trial Profile  
 
 
Assessed for eligibility (between 11 to 14 weeks’ 
gestation and twin gestations) (n) 
Excluded (n)  
- Did not consent  
- Did not meet 
inclusion criteria  
- Met exclusion 
criteria  
Randomized 1:1 into two groups 
Control Group (no intervention) (n) Combined Vaginal Progesterone 










between 11- and 
14-weeks’ 
gestation and 
400mg of vaginal 
progesterone daily 
until delivery or 
37 weeks’ 
gestation   
Analyzed in the Control Group (n) 
(including lost to follow-up and 
withdrawals of participation)  
Analyzed in Combined Vaginal 
Progesterone and Cervical Pessary 
Group (n) (including lost to follow-up 







Appendix C: Maternal Demographic and Medical History Data Collection  




Control Group (n=122) Combined Vaginal 
Progesterone and Cervical 
Pessary Group (n=122) 
Maternal age at time of 
enrolment  
  
Maternal gestational age at 
time of enrolment 
  
Education Level   
Ethnicity    
Body-Mass Index during 
pregnancy  
  
Gravidity and Parity    
Marital Status    
Household Monthly Income   
Behaviors During 
Pregnancy 
Control Group (n=122) Combined Vaginal 
Progesterone and Cervical 
Pessary Group (n=122) 
Alcohol Consumption   
Actively Smoking   
Passively Smoking   
Highly Active Level   
Folic Acid Supplementation   
Illicit Drug Use   
Screening    
Pregnancy Outcomes Control Group (n=122) Combined Vaginal 
Progesterone and Cervical 




Gestational diabetes mellitus   
Anxiety   
Depression   
GBS colonization   





Mullerian anomaly    
Bacterial vaginosis    
HELLP Syndrome   
Abortion   














































Appendix D: Pregnancy Outcomes (Detailed) 

















Total Deliveries      
<28 weeks       
28 – 30 weeks       
30 to 32 weeks      
32 to 34 weeks      
34 to 36 weeks      
>37 weeks      
Preterm < 37 weeks      
Full-term      
Spontaneous 
Deliveries  
     
<28 weeks       
28 – 30 weeks       
30 to 32 weeks      
32 to 34 weeks      
34 to 36 weeks      
>37 weeks      
Preterm < 37 weeks      
Full-term      
Induction Required       
Post-term      
PROM      
Placental abruption      
Hypertension      
Gestational 
Diabetes  
     
Oligohydramnios 
or IUGR 
     
Fetal Distress      







     
Operative Vaginal 
Birth 
     
Caesarean section 
prior to labor 
     
Caesarean section 
after onset of labor  
     
Neonatal Outcomes      
Live births      
Death prior to 
discharge from 
hospital 
     
Admission to 
NICU  
     
APGAR Score at 1 
minute 
     
APGAR Score at 5 
minutes 
     
Respiratory distress 
syndrome 
     
Intravascular 
hemorrhage 
     
Sepsis      
Necrotizing 
enterocolitis  
     
BW <1,500g      
BW <2,500g      
BW ≥ 2,500g      
Adherence to 
Treatment 
     
≥80% of vaginal 
progesterone 
     
≥50% of vaginal 
progesterone 
     
Adverse Effects of 
Interventions 
     
Vaginal Discharge      
Pain      
Itching      
Bleeding      






Appendix E: Sample Size Calculations  
Completed using G*Power, version 3.1.9.6. for MacOS 
- Based on 20% reduction of reported 60% preterm birth rate in twin 
gestations prior to 37 weeks 
- Using Cox Proportional Hazard Regression 
- α error = 0.05 
- β error = 20% 
- Power = 80% 
- Calculated to be 97 in each arm  
 
- Accounting for maximum loss to follow-up = 25%  
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